JAK1/2 inhibitor ruxolitinib reduces aggregates in cardiac proteinopathy.

EMBO Mol Med · 2026 · PMC13179346 · PMID 41917326

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

There were no significant differences in absolute force among all treatment groups, although there was a clear trend towards lower force with 30 μM ruxolitinib.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.